Western Wealth Management LLC Has $2.33 Million Stock Holdings in Johnson & Johnson $JNJ

Western Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,282 shares of the company’s stock after buying an additional 550 shares during the quarter. Western Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,334,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the period. Northern Trust Corp boosted its holdings in Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after buying an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after purchasing an additional 620,039 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after buying an additional 712,181 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Scotiabank started coverage on Johnson & Johnson in a report on Thursday. They set a “sector outperform” rating and a $230.00 price objective on the stock. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ stock opened at $197.83 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $197.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50 day simple moving average of $185.81 and a two-hundred day simple moving average of $170.14. The company has a market cap of $476.64 billion, a P/E ratio of 19.05, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.